FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280578214> ?p ?o ?g. }

• W4280578214 endingPage "2272" @default.
• W4280578214 startingPage "2265" @default.
• W4280578214 abstract "Hepatitis C virus (HCV) genotype 6 mainly distributes in Southeast Asia and South China. Because of the low prevalence in developed countries, optimal treatment for HCV genotype 6 in real-world setting remains to be determined. We aimed to evaluate the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV genotype 6 infection in Taiwan.A total of 286 patients with chronic hepatitis C (CHC) genotype 6, 161 receiving 12-week SOF/VEL and 125 receiving 8-week GLE/PIB, were enrolled. All patients were followed up for 12 weeks after treatment completion. Demographic information, HCV viral load (VL), profiles of lipid and sugar, and adverse events were recorded and reviewed.Sustained virological response (SVR) rates of SOF/VEL and GLE/PIB evaluated by intention-to-treat analysis were 99.38% and 100%, respectively. SVR achieved 100%, regardless of cirrhosis or viral load (cutoff: 6 MIU/mL), of both regimens by per-protocol analysis. Skin itching was the most common adverse event, with an overall incidence of 6.64% which was more prevalent in GLE/PIB (12.0%) than SOF/VEL (2.48%). A significant decrease in the estimated glomerular filtration rate was observed in patients receiving SOF/VEL but not in those receiving GLE/PIB at the time of SVR. No patient discontinued treatment due to adverse event.The high SVR and excellent safety of SOF/VEL and GLE/PIB in real-world setting reveals that the two DAA regimens are favorable options for treatment of HCV genotype 6 in Taiwan and Asia." @default.
• W4280578214 created "2022-05-22" @default.
• W4280578214 creator A5005490187 @default.
• W4280578214 creator A5010955867 @default.
• W4280578214 creator A5027315505 @default.
• W4280578214 creator A5072280230 @default.
• W4280578214 creator A5075846648 @default.
• W4280578214 creator A5090245512 @default.
• W4280578214 creator A5090991069 @default.
• W4280578214 date "2022-11-01" @default.
• W4280578214 modified "2023-10-14" @default.
• W4280578214 title "Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C" @default.
• W4280578214 cites W1578834103 @default.
• W4280578214 cites W1970449031 @default.
• W4280578214 cites W1975184667 @default.
• W4280578214 cites W1986925440 @default.
• W4280578214 cites W1987665333 @default.
• W4280578214 cites W2070358004 @default.
• W4280578214 cites W2086388926 @default.
• W4280578214 cites W2138619940 @default.
• W4280578214 cites W2147437748 @default.
• W4280578214 cites W2320330796 @default.
• W4280578214 cites W2578013986 @default.
• W4280578214 cites W2605698336 @default.
• W4280578214 cites W2608471646 @default.
• W4280578214 cites W2615084726 @default.
• W4280578214 cites W2667085915 @default.
• W4280578214 cites W2735669709 @default.
• W4280578214 cites W2746084941 @default.
• W4280578214 cites W2751450406 @default.
• W4280578214 cites W2756644889 @default.
• W4280578214 cites W2761085897 @default.
• W4280578214 cites W2792190643 @default.
• W4280578214 cites W2809785330 @default.
• W4280578214 cites W2899084700 @default.
• W4280578214 cites W2901283193 @default.
• W4280578214 cites W2905538085 @default.
• W4280578214 cites W2953775043 @default.
• W4280578214 cites W2968677045 @default.
• W4280578214 cites W2983402505 @default.
• W4280578214 cites W2990066475 @default.
• W4280578214 cites W3006658062 @default.
• W4280578214 cites W3080728644 @default.
• W4280578214 cites W3081688931 @default.
• W4280578214 cites W3187606337 @default.
• W4280578214 cites W4255721852 @default.
• W4280578214 cites W754726257 @default.
• W4280578214 doi "https://doi.org/10.1016/j.jfma.2022.04.020" @default.
• W4280578214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35581112" @default.
• W4280578214 hasPublicationYear "2022" @default.
• W4280578214 type Work @default.
• W4280578214 citedByCount "1" @default.
• W4280578214 countsByYear W42805782142022 @default.
• W4280578214 crossrefType "journal-article" @default.
• W4280578214 hasAuthorship W4280578214A5005490187 @default.
• W4280578214 hasAuthorship W4280578214A5010955867 @default.
• W4280578214 hasAuthorship W4280578214A5027315505 @default.
• W4280578214 hasAuthorship W4280578214A5072280230 @default.
• W4280578214 hasAuthorship W4280578214A5075846648 @default.
• W4280578214 hasAuthorship W4280578214A5090245512 @default.
• W4280578214 hasAuthorship W4280578214A5090991069 @default.
• W4280578214 hasBestOaLocation W42805782141 @default.
• W4280578214 hasConcept C120665830 @default.
• W4280578214 hasConcept C121332964 @default.
• W4280578214 hasConcept C126322002 @default.
• W4280578214 hasConcept C197934379 @default.
• W4280578214 hasConcept C203014093 @default.
• W4280578214 hasConcept C2522874641 @default.
• W4280578214 hasConcept C2776408679 @default.
• W4280578214 hasConcept C2776455275 @default.
• W4280578214 hasConcept C2778390639 @default.
• W4280578214 hasConcept C2780040827 @default.
• W4280578214 hasConcept C61511704 @default.
• W4280578214 hasConcept C71924100 @default.
• W4280578214 hasConcept C90924648 @default.
• W4280578214 hasConceptScore W4280578214C120665830 @default.
• W4280578214 hasConceptScore W4280578214C121332964 @default.
• W4280578214 hasConceptScore W4280578214C126322002 @default.
• W4280578214 hasConceptScore W4280578214C197934379 @default.
• W4280578214 hasConceptScore W4280578214C203014093 @default.
• W4280578214 hasConceptScore W4280578214C2522874641 @default.
• W4280578214 hasConceptScore W4280578214C2776408679 @default.
• W4280578214 hasConceptScore W4280578214C2776455275 @default.
• W4280578214 hasConceptScore W4280578214C2778390639 @default.
• W4280578214 hasConceptScore W4280578214C2780040827 @default.
• W4280578214 hasConceptScore W4280578214C61511704 @default.
• W4280578214 hasConceptScore W4280578214C71924100 @default.
• W4280578214 hasConceptScore W4280578214C90924648 @default.
• W4280578214 hasIssue "11" @default.
• W4280578214 hasLocation W42805782141 @default.
• W4280578214 hasLocation W42805782142 @default.
• W4280578214 hasOpenAccess W4280578214 @default.
• W4280578214 hasPrimaryLocation W42805782141 @default.
• W4280578214 hasRelatedWork W2258641314 @default.
• W4280578214 hasRelatedWork W2322431879 @default.
• W4280578214 hasRelatedWork W2584621488 @default.
• W4280578214 hasRelatedWork W2585250246 @default.
• W4280578214 hasRelatedWork W2603358003 @default.

• next